Antibody responses to macrocycles in lymphoma

Journal of Nuclear Medicine

Volumn 37, Issue 3, 1996, Pages 451-456

  DeNardo, G L ^a   Mirick, G R ^b   Kroger, L A ^b   O'Donnell, R T ^b   Meares, C F ^b   DeNardo, S J ^b  

^a Molecular Cancer Institute   (United States)

^b NONE

Author keywords

anti macro cycle antibodies; HAMA; lymphoma; radioimmunotherapy

Indexed keywords

HAPTEN; MACROCYCLIC COMPOUND;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOMA; MALE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SERUM SICKNESS;

ANIMALS; ANTIBODY FORMATION; COPPER RADIOISOTOPES; EDETIC ACID; FEMALE; HETEROCYCLIC COMPOUNDS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INDIUM RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; MALE; MICE; MIDDLE AGED; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY;

EID: 0029866472     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Moi MK, Meares CF, McCall MJ, Cole WC, DeNardo SJ Copper chelates as probes of biological Systems: stable copper complexes with a macrocyclic bifunctional chelating agent Anal Biochem 1985;148:249-253.
2. Moi MK, Meares CF, DeNardo SJ. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,-N′,N″,N‴- tetraacetic acid and study of its yttrium (III) complex. J Am Chem Soc 1988,110:6266-6267.
3. Deshpande SV, DeNardo SJ, Kukis DL, et al. Yttrium-90-labeled monoclonal antibody for therapy labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990;31:473-479.
4. Meares CF, Moi MK, Diril H, et al Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer 1990;63(suppl X):21-26.
5. Snook DE, Rowlinson G, Meares CF, Epenetos AA. Indium-111- and yttrium-90-labeled macrocyclic chelating agents. In: AA Epenetos, ed. Monoclonal antibodies. London: Chapman and Hall, 1991 157-166.
6. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions Anal Biochem 1984,142.68-78
7. Kukis DK, Diril H, Greiner DP, et al. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer 1994; 73(suppl):779-786.
8. Goldenberg DM. Radioimmunotherapy of human colonic cancer xenografts with yttrium-90-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 1988;48:3270-3275
9. Stewart JS, Hird V, Snook D, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer J Clin Oncol 1990;8:1941-1950.
10. I. Cancer Res 1993;53:5727-5733.
11. 2+. Helvetica Chimica Acta 1986;69:2081-2086.
12. Smith-Jones P, Fridrich R, Kaden TA, et al. Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-tetraazacyclotetradec-1-yl) methyl]benzoic acid Bioconj Chem 1991;2:415-421.
13. Parker D. Tumor targeting with radiolabeled macrocycle-antibody conjugates. Chem Soc Rev 1990,19 271-291.
14. Gansow OA Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl Med Biol 1991;18:369-381
15. Kosmas C, Snook D, Gooden CS, et al. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 1992,52:904-911.
16. Kosmas C, Snook DE, Gooden CS, et al. Immunogenicity of a macrocyclic chelating agent (DOTA) in patients receiving radiolabeled antibody-guided imaging and therapy. In: AA Epenetos, ed. Monoclonal antibodies 2 London, Chapman and Hall, 1993. 39-51.
17. Weiner EC, Brechbiel MW, Brothers H, et al. Dendrimer-based metal chelates, a new class of magnetic imaging contrast agents. Mag Res Med 1994;31:1-8
18. Wu C, Brechbiel MW, Kozak RW, Gansow OA. Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging. Bioorg Med Chem Lett 1994,4:449-454.
19. Hainfeld JF, Foley CJ, Srivastava SC, et al Radioactive gold cluster immunoconjugates potential agents for cancer therapy Intl J Rad Appl Instr, Part B, Nucl Med Biol 1990,17:287-294.
20. DeNardo GL, DeNardo SJ, Meares CF, et al Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and in patients with lymphoma. Antibod Immunoconj Radiopharm 1991;4:777-785
21. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies. Lym-1 and Lym-2, reactive with human B lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential Cancer Res 1987,47:830-840.
22. McCall MJ, Diril H, Meares CF. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconj Chem 1990; 2.222-226.
23. Deshpande SV, DeNardo SJ, Meares CF, et al. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy labeling and biodistribution in Raji tumored mice J Nucl Med 1988;29:217-225
24. DeNardo SJ, DeNardo GL, Deshpande SV, et al. The design of a radiolabeled monoclonal antibody for radioimmunodiagnosis and radioimmunotherapy, In. SC Srivastiva, ed. Radiolabeled monoclonal antibodies for imaging and therapi New York: Plenum; 1988 293-310.
25. HAMA Survey Group. Survey of methods for measuring human anti-mouse antibodies Clin Chim Acta 1993;215.153-163
26. Khazaeli MR, Conry RM, LoBuglio AF Human immune response to monoclonal antibodies. J Immunother 1994;15:42-52.
27. Hollander M, Wolfe DA Nonparametric statistical methods New York: Wiley 1973.
28. DeNardo GL, Kroger LA, DeNardo SJ, et al Comparative toxicity studies of yttrium-90 MX-DTPA and 2IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 1994;73:1012-1021
29. Hird V, Verhoeyen M, Badley RA, et al. Tumour localization with a radioactively labelled reshaped human monoclonal antibody. Br J Cancer 1991,64 911-914
30. 131I-Lym-1. Int J Biol Markers 1995;10:67-74.
31. Johnson DA, Barton RL, Fix DV, Scott WL, Gutowski MC. Induction of immunogenicity of monoclonal antibodies by conjugation with drags Cancer Res 1991,51.5774-5776
32. Goodwin DA, Meares CF, McCall MJ, McFigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988;29:226-234.
33. Watanabe N, Goodwin DA, Meares CF, et al. Immunogenicity in rabbits and mice of an antibody-chelate conjugate, comparison of (S) and (R) macrocyclic enantiomers and an acyclic chelating agent. Cancer Res 1994;54 1049-1054.
34. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan Jr AC Human anti-mouse immunoglobulin responses m patients receiving monoclonal antibody therapy Cancer Res 1985,45 879-885.
35. Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature 1985;316 265-267.
36. Kosmas C, Maraveyas A, Gooden CS, Snook D, Epenetos AA. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. J Nucl Med 1995,36:746-753.